124I Radiolabeling of a Au
            III-NHC Complex for In Vivo Biodistribution Studies

Federica Guarra; Alessio Terenzi; Christine Pirker; Rossana Passannante; Dina Baier; Ennio Zangrando; Vanessa Gomez-Vallejo; Tarita Biver; Chiara Gabbiani; Walter Berger; Jordi Llop; Luca Salassa

doi:10.1002/anie.202008046

¹²⁴I Radiolabeling of a Au ^III-NHC Complex for In Vivo Biodistribution Studies

Federica Guarra
, Alessio Terenzi (Corresponding author)
, Christine Pirker
, Rossana Passannante
, Dina Baier
, Ennio Zangrando
, Vanessa Gomez-Vallejo
, Tarita Biver
, Chiara Gabbiani
, Walter Berger (Corresponding author)
, Jordi Llop (Corresponding author)
, Luca Salassa (Corresponding author)

Department of Inorganic Chemistry

Publications: Contribution to journal › Article › Peer Reviewed

Abstract

Au(III)complexes with N-heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new Au-III-NHC complexes by direct oxidation with radioactive [I-124]I(2)as a valuable strategy to monitor the in vivo biodistribution of this class of compounds using positron emission tomography (PET). While in vitro analyses provide direct evidence for the importance of Au-III-to-Au(I)reduction to achieve full anticancer activity, in vivo studies reveal that a fraction of the Au-III-NHC prodrug is not immediately reduced after administration but able to reach the major organs before metabolic activation.

Original language	English
Pages (from-to)	17130-17136
Number of pages	7
Journal	Angewandte Chemie (International Edition)
Volume	59
Issue number	39
DOIs	https://doi.org/10.1002/anie.202008046
Publication status	Published - 21 Sept 2020

Funding

A.T. has received funding from the EU Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Actions grant no. 746976. We acknowledge financial support from the Severo Ochoa Centres of Excellence Programme run by the Spanish State Research Agency (ref. CEX2018-000867-S, L.S., DIPC), the Spanish Ministry of Economy and Competitiveness (CTQ2017-87637-R, J.L.), the Beneficentia Stiftung, and the University of Pisa (PRA_2017_25 grant, C.G.), and from the Austrian Science Fund (FWF; project numbers L212 and L568, W.B.). We thank M. Stojanovic and P. Vician for excellent technical assistance, and the Spanish MultiMetDrugs network (RED2018-102471-T) for fruitful discussions.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Austrian Fields of Science 2012

104003 Inorganic chemistry
301904 Cancer research
104020 Radiochemistry

Keywords

anticancer
metallodrugs
N-heterocyclic carbenes
positron emission tomography
radiochemistry
HETEROCYCLIC CARBENE COMPLEXES
COORDINATED GOLD COMPOUND
GOLD(III) COMPLEXES
ANTICANCER
AURANOFIN
CHEMISTRY
INSIGHTS
BIOLOGY
VITRO

Access to Document

10.1002/anie.202008046

Cite this

@article{25b288c55ec0475cbf7b4bb26fafd38b,

title = "124I Radiolabeling of a Au III-NHC Complex for In Vivo Biodistribution Studies",

abstract = "Au(III)complexes with N-heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new Au-III-NHC complexes by direct oxidation with radioactive [I-124]I(2)as a valuable strategy to monitor the in vivo biodistribution of this class of compounds using positron emission tomography (PET). While in vitro analyses provide direct evidence for the importance of Au-III-to-Au(I)reduction to achieve full anticancer activity, in vivo studies reveal that a fraction of the Au-III-NHC prodrug is not immediately reduced after administration but able to reach the major organs before metabolic activation.",

keywords = "anticancer, metallodrugs, N-heterocyclic carbenes, positron emission tomography, radiochemistry, HETEROCYCLIC CARBENE COMPLEXES, COORDINATED GOLD COMPOUND, GOLD(III) COMPLEXES, ANTICANCER, AURANOFIN, CHEMISTRY, INSIGHTS, BIOLOGY, VITRO",

author = "Federica Guarra and Alessio Terenzi and Christine Pirker and Rossana Passannante and Dina Baier and Ennio Zangrando and Vanessa Gomez-Vallejo and Tarita Biver and Chiara Gabbiani and Walter Berger and Jordi Llop and Luca Salassa",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Published by Wiley-VCH Verlag GmbH \& Co. KGaA",

year = "2020",

month = sep,

day = "21",

doi = "10.1002/anie.202008046",

language = "English",

volume = "59",

pages = "17130--17136",

journal = "Angewandte Chemie (International Edition)",

issn = "1433-7851",

publisher = "WILEY-V C H VERLAG GMBH",

number = "39",

}

TY - JOUR

T1 - 124I Radiolabeling of a Au III-NHC Complex for In Vivo Biodistribution Studies

AU - Guarra, Federica

AU - Terenzi, Alessio

AU - Pirker, Christine

AU - Passannante, Rossana

AU - Baier, Dina

AU - Zangrando, Ennio

AU - Gomez-Vallejo, Vanessa

AU - Biver, Tarita

AU - Gabbiani, Chiara

AU - Berger, Walter

AU - Llop, Jordi

AU - Salassa, Luca

PY - 2020/9/21

Y1 - 2020/9/21

N2 - Au(III)complexes with N-heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new Au-III-NHC complexes by direct oxidation with radioactive [I-124]I(2)as a valuable strategy to monitor the in vivo biodistribution of this class of compounds using positron emission tomography (PET). While in vitro analyses provide direct evidence for the importance of Au-III-to-Au(I)reduction to achieve full anticancer activity, in vivo studies reveal that a fraction of the Au-III-NHC prodrug is not immediately reduced after administration but able to reach the major organs before metabolic activation.

AB - Au(III)complexes with N-heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new Au-III-NHC complexes by direct oxidation with radioactive [I-124]I(2)as a valuable strategy to monitor the in vivo biodistribution of this class of compounds using positron emission tomography (PET). While in vitro analyses provide direct evidence for the importance of Au-III-to-Au(I)reduction to achieve full anticancer activity, in vivo studies reveal that a fraction of the Au-III-NHC prodrug is not immediately reduced after administration but able to reach the major organs before metabolic activation.

KW - anticancer

KW - metallodrugs

KW - N-heterocyclic carbenes

KW - positron emission tomography

KW - radiochemistry

KW - HETEROCYCLIC CARBENE COMPLEXES

KW - COORDINATED GOLD COMPOUND

KW - GOLD(III) COMPLEXES

KW - ANTICANCER

KW - AURANOFIN

KW - CHEMISTRY

KW - INSIGHTS

KW - BIOLOGY

KW - VITRO

UR - https://www.scopus.com/pages/publications/85088799570

U2 - 10.1002/anie.202008046

DO - 10.1002/anie.202008046

M3 - Article

SN - 1433-7851

VL - 59

SP - 17130

EP - 17136

JO - Angewandte Chemie (International Edition)

JF - Angewandte Chemie (International Edition)

IS - 39

ER -